Addex Therapeutics Stock (NASDAQ:ADXN), Trade Ideas

Addex Therapeutics

Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACDC

ADXN

BACK

BENF

BNED

BSGM

CGEM

CLDI

CSLR

CTNM

DFLI

DYNT

ERIC

ITCI

JAGX

KAVL

MCBC

MNSO

PACB

PALI

PRFX

PRSO

PRZO

RNAC

RVYL

SKIL

SMXT

SPRC

SXTC

SYTA

TAOP

WISA

WFTC

Shares of  Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

ENSV

GRPN

KXIN

SHPH

SPCB

USEG

Shares of  Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into a definiti

Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

ANGH

BCLI

BPTS

DXYZ

FAAS

FCUV

GHSI

HALO

HRYU

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MDIA

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

SNGX

VBIV

VINC

WAVE

Shares of  Biophytis S.A.  (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics Ltd

With the potential legalization of adult-use marijuana under Amendment 3, Florida&#39;s cannabis market is set for a significant transformation. <a href="https://www.benzinga.com/topic/florida-cannabis">Florida&#39;s legal cannabis</a> spending is projected to grow at a 12% CAGR from 2023 to 2028, with total sales expected to reach $4.5 billion by 2028, positioning Florida as the second-largest U.S. cannabis market after California.
<h3>Competitive Landscape And Consumer Behavior</h3>
Florida&#39;s retail cannabis landscape has already shown significant growth, with the number of dispensaries rising to 628 by April 2024, as per&nbsp;<a href="https://www.benzinga.com/topic/bdsa">BDSA</a> data.&nbsp;
The state&#39;s medical cannabis sector remains robust, with patient numbers surpassing 878,000 this month and sales reaching $2.6 billion in 2023, marking an 18% increase from the previous year.
As Florida prepares for a November ballot initiative on adult-use legalization, BDSA analyst Brendan Mitchel-Chesebro underscores the legislative uncertainty around <a href="https://www.benzinga.com/markets/cannabis/24/04/38299011/its-on-the-ballot-the-future-of-adult-use-cannabis-in-florida-whats-the-contingency-plan-if-lega">Amendment 3</a>, which allows but does not require the expansion of adult-use cannabis licenses.
This leaves the future market landscape uncertain. If the initiative passes, BDSA forecasts sales of $874 million in 2025 for the adult-use segment.
In this context, existing operators like <a href="https://www.benzinga.com/markets/cannabis/24/04/38313915/cannabis-in-florida-the-bellamy-brothers-tell-trulieve-ceo-we-rolled-a-fat-one-when-legalization">Trulieve</a> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tcnnf#OTC">TCNNF</a>) are advised to refine their strategies to cater to a potentially larger and more diverse consumer base.
As consumer penetration rates are expected to surge&mdash;mirroring trends observed in other states transitioning to adult use&mdash;companies must adeptly navigate evolving preferences across different product forms and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37666783/marijuana-shoppers-favorite-strains-2024">usage motivations</a> to maintain or enhance their market shares.
Mitchel-Chesebro points out that, unlike other adult-use markets, only 31% of Florida consumers currently prioritize <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38341510/how-to-max-profits-this-420-smart-discounts-amid-sales-spike-of-premium-marijuana">low-cost</a>, compared to 36% in general adult-use markets.
However, the typical initial price increase following legalization might heighten price sensitivity among <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin">Florida shoppers</a>.
This, along with the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36268367/u-s-cannabis-market-premium-products">growing popularity of infused pre-rolls</a> and a notable 47% year-over-year growth in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33369455/sweet-treats-take-over-gummie-consumption-outpaces-flower-in-latest-consumer-data-h">edibles sales</a>, indicates significant upcoming shifts in consumer behavior as the market expands.
<h3>Strategies For Market Entry And Expansion</h3>
As the Florida market braces for a likely uptick in mergers and acquisitions, Mitchel-Chesebro advises new entrants and expanding firms to adopt a nuanced pricing strategy.
Using BDSA&rsquo;s Price Tiers analysis, he highlights the potential for brands to capitalize on specific product segments where premium offerings are underrepresented relative to their market performance.
For example, in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35991290/analyst-inside-look-trends-and-opportunities-in-ohios-emerging-recreational-cannabi">markets like Ohio</a>, premium-priced flower products disproportionately contribute to sales relative to their market availability. Identifying and targeting these lucrative price tiers can be a key strategy for newly introduced brands aiming for rapid growth in new markets.
Photo: AI-Generated Image.&nbsp;

Analyst Color

Cannabis

Government

Market Summary

Regulations

Emerging Markets

Retail Sales

Exclusives

Analyst Ratings

Interview

General

TCNNF

Landing In Florida's Cannabis Market: Legal Adult-Use Marijuana Could Yield $874M In 2025

<h3 class="wp-block-heading">Health Recall: Microbial Contamination Alert In British Columbia</h3>
In an uncommon event, <a href="https://recalls-rappels.canada.ca/en/alert-recall/sirona-pharma-inc-acreage-pharms-ltd-recalls-one-lot-full-sesh-purple-gelato-punch">Health Canada </a><a href="https://recalls-rappels.canada.ca/en/alert-recall/sirona-pharma-inc-acreage-pharms-ltd-recalls-one-lot-full-sesh-purple-gelato-punch">recalls Sirona Pharma Inc.&#8217;s Full Sesh Purple Gelato Punch</a> dried cannabis sold in British Columbia due to microbial contamination. The recall responds to a quality control measure.
<a href="https://www.benzinga.com/markets/cannabis/23/09/34548455/medical-cannabis-in-canada-faces-decline-whats-behind-the-38-drop-in-registrations">Health Canada&#8217;s </a>Cannabis Data Gathering Program identified microbial contaminant levels exceeding specified limits, potentially posing health risks. While no adverse health reports have been received, consumers have been alerted and are advised to cease using the recalled product immediately. With 1200 units sold between September 18, 2023, and April 18, 2024, the product must be returned to retailers or disposed of safely. Further specification on the contaminant was not made public. 
<h3 class="wp-block-heading">Manitoba&#8217;s Home Cultivation Ban Reversal: Shifting Regulations</h3>
Manitoba&#8217;s political landscape is undergoing a significant shift as the <a href="https://winnipeg.citynews.ca/2024/04/19/manitoba-set-to-remove-provinces-ban-on-growing-cannabis/">provincial government plans to overturn its ban on homegrown cannabis cultivation</a>. Aligned with federal law and evolving societal attitudes, this reversal reflects changing political dynamics and public sentiment regarding cannabis regulations.
The decision comes as Manitoba and Quebec were the only provinces to enforce restrictions against growing adult-use marijuana at home following <a href="https://www.benzinga.com/topic/canada-cannabis">Canada&#8217;s </a>legalization of recreational cannabis in 2018. With the New Democratic Party of Manitoba (NDP) now in power, the province anticipates lifting the ban, marking a pivotal moment in cannabis policy reform.
<h3 class="wp-block-heading">International Expansion: Greenway Greenhouse Cannabis Corporation Receives Certifications</h3>
In other news, <a href="https://www.benzinga.com/markets/cannabis/23/09/34951623/greenway-greenhouse-cannabis-launches-first-brands-in-the-canadian-market">Greenway Greenhouse</a> Cannabis Corporation (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GWAY#CSE">GWAY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GWAYF#OTCQB">GWAYF</a>) <a href="https://www.prnewswire.com/news-releases/greenway-receives-international-cannabis-accreditation-302128092.html">announced </a>a significant milestone as its cultivation facility in Leamington, Ontario receives CUMS-GAP and GACP certification. This achievement positions Greenway to distribute its high-quality greenhouse cannabis internationally, tapping into new markets and revenue streams.
The certifications, completed through Control Union, demonstrate compliance with strict international standards, allowing Greenway to engage with multiple international cannabis purchasers. With an annual cultivation capacity of 24,000 kg, Greenway aims to capitalize on the export market&#8217;s potential, enhancing revenue, gross margins, and global presence.
&#8220;Receiving these certifications opens up a whole new world of opportunities for Greenway,&#8221; said Jamie D&#8217;Alimonte, CEO of Greenway. &#8220;With our most recent expansion, we are able to scale up production to meet any new demand for our product internationally.&#8221;
As Canada&#8217;s cannabis industry continues to evolve, these developments signal both challenges and opportunities for stakeholders, shaping the future of cannabis regulation, consumer safety and market expansion.

Media

CSE:GWAY

GWAYF

Canada Cannabis Update: Health Recall, Home Cultivation Ban Reversal, International Expansion

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 5 years by 5.0% on an annualized basis producing an average annual return of 16.57%. Currently, IDEXX Laboratories has a market capitalization of $41.47 billion. 
Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 5 years ago, it would be worth $2,164.47 today based on a price of $499.30 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714167027_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IDXX

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 10 years by 13.17% on an annualized basis producing an average annual return of 23.61%. Currently, Progressive has a market capitalization of $121.84 billion. 
Buying $1000 In PGR: If an investor had bought $1000 of PGR stock 10 years ago, it would be worth $8,578.56 today based on a price of $208.03 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714167022_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth $8,600 Today

During the last three months, 4 analysts shared their evaluations of Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bread Finl Hldgs, presenting an average target of $34.75, a high estimate of $48.00, and a low estimate of $26.00. Surpassing the previous average price target of $30.33, the current average has increased by 14.57%.
<img src="https://www.benzinga.com/files/images/story/2024/1714165300_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bread Finl Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Bill Carcache</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bread Finl Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bread Finl Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bread Finl Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bread Finl Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BFH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bread Finl Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Bread Finl Hldgs</h2>
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains minority interest in its recently spun-off LoyaltyOne division, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
<h3>Financial Milestones: Bread Finl Hldgs's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Bread Finl Hldgs's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -1.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Bread Finl Hldgs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bread Finl Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bread Finl Hldgs's debt-to-equity ratio is below the industry average at 1.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Bread Finl Hldgs

In the preceding three months, 4 analysts have released ratings for Reliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $360.5, a high estimate of $380.00, and a low estimate of $345.00. This upward trend is apparent, with the current average reflecting a 17.24% increase from the previous average price target of $307.50.
<img src="https://www.benzinga.com/files/images/story/2024/1714165265_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Reliance. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Daniel Knauff</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$362.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reliance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Reliance compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Reliance's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Reliance analyst ratings.</a>
<h2>About Reliance</h2>
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
<h3>Understanding the Numbers: Reliance's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Reliance's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -7.57% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Reliance's net margin excels beyond industry benchmarks, reaching 8.17%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Reliance's ROE excels beyond industry benchmarks, reaching 3.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Reliance's ROA excels beyond industry benchmarks, reaching 2.6%. This signifies efficient management of assets and strong financial health.
Debt Management: Reliance's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Reliance

Analysts' ratings for VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated VF and provided 12-month price targets. The average target is $16.38, accompanied by a high estimate of $22.00 and a low estimate of $12.00. A 9.25% drop is evident in the current average compared to the previous average price target of $18.05. 
<img src="https://www.benzinga.com/files/images/story/2024/1714165258_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive VF. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laurent Vasilescu</td>
<td>Exane BNP Paribas</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.50</td>
<td>$15.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to VF. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of VF compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of VF's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of VF's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VFC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on VF analyst ratings.</a>
<h2>Get to Know VF Better</h2>
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
<h3>Unraveling the Financial Story of VF</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: VF's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -16.16%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: VF's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): VF's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.97%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): VF's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.33%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: VF's debt-to-equity ratio stands notably higher than the industry average, reaching 3.48. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Assess VF: What You Need To Know

Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) has outperformed the market over the past 15 years by 3.58% on an annualized basis producing an average annual return of 15.74%. Currently, Eagle Materials has a market capitalization of $8.84 billion. 
Buying $100 In EXP: If an investor had bought $100 of EXP stock 15 years ago, it would be worth $921.72 today based on a price of $256.70 for EXP at the time of writing.
<h3>Eagle Materials's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714165230_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $900 Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 4.87% on an annualized basis producing an average annual return of 15.31%. Currently, Apollo Global Management has a market capitalization of $63.76 billion. 
Buying $100 In APO: If an investor had bought $100 of APO stock 10 years ago, it would be worth $413.64 today based on a price of $112.22 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714165225_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

Ratings for Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.57, a high estimate of $32.00, and a low estimate of $18.00. This current average reflects an increase of 22.85% from the previous average price target of $20.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1714165216_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Vital Farms's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ben Klieve</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ben Klieve</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Adam Samuelson</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vital Farms. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vital Farms compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Vital Farms's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vital Farms's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VITL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vital Farms analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Vital Farms</h2>
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter &amp; Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
<h3>Vital Farms: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Vital Farms showcased positive performance, achieving a revenue growth rate of 23.37% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.31%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Vital Farms's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vital Farms's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.75%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VITL

Breaking Down Vital Farms: 7 Analysts Share Their Views

<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38327580/exclusive-kind-founders-reveal-how-theyre-building-a-better-web3-for-creators-gamers-and-c">Kind</a>, the innovative Web3 creators agency known for enhancing the digital experiences of creators and gamers, recently hosted one of the largest online parties in Web 3 history.&nbsp;This <a href="http://www.benzinga.com/markets/cryptocurrency/24/02/37252915/exclusive-pixels-web3-gaming-revolution-luke-barwikowski-tells-all">monumental event on </a><a href="http://www.benzinga.com/markets/cryptocurrency/24/02/37252915/exclusive-pixels-web3-gaming-revolution-luke-barwikowski-tells-all">Pixels</a> attracted up to 126,000 players, witnessed by over 2,500 viewers on Twitch, and connected more than 100 key opinion leaders (KOLs) simultaneously.
<blockquote class="twitter-tweet">126K USERS SHOWED UP TO THE <a href="https://twitter.com/Kind_HQ?ref_src=twsrc%5Etfw">@Kind_HQ</a> ENERGY PARTY LETS GOOOOOO
&mdash; heidi (@heidichristne) <a href="https://twitter.com/heidichristne/status/1781350014046101662?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>See also:<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38327580/exclusive-kind-founders-reveal-how-theyre-building-a-better-web3-for-creators-gamers-and-c">&nbsp;Kind Founders Reveal How They&#39;re Building A Better Web3 For Creators, Gamers And Communities</a>
The party wasn&#39;t just about breaking records; it was a showcase of community and technology. Attendees enjoyed a slew of rewards, including Pixels tokens, TEK Guild memberships, and VIP in-game passes, enhancing their interactive experience.
This event marks a significant milestone in the Web3 community, demonstrating Kind&rsquo;s commitment to building a more engaging and rewarding platform for creators and gamers alike. As Web3 continues to evolve, Kind is at the forefront, pushing the boundaries of what&#39;s possible in virtual spaces.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37252915/exclusive-pixels-web3-gaming-revolution-luke-barwikowski-tells-all" target="_blank">EXCLUSIVE: Pixels&#39; Web3 Gaming Revolution - Luke Barwikowski Tells All</a>
In the aftermath of their successful event, Kind took to X to express heartfelt thanks to everyone who played a pivotal role in the organization and execution of their massive online party in Pixels. They extended their gratitude to <a href="https://x.com/kyleblohm?s=21">Kyle Blohm</a> for his expertise in crafting the event, and to Heidi Christne for her pivotal role in making the event possible. Appreciation was also shown to <a href="https://x.com/chief_axiegg?s=21">Chief</a>&nbsp;for an enthralling Twitch stream, and to partners like TEK and <a href="https://twitter.com/TriballyGames">Tribally Games</a> for their significant contributions to the event&#39;s success in the Pixels ecosystem. Additionally, Kind acknowledged <a href="https://x.com/e4e_gg?s=21">Esports4Everyone</a>, Sourbeck, and Covetor for their exceptional efforts in stream production, which peaked at over 2,700 viewers on Twitch.
<blockquote class="twitter-tweet">126000 Players attended the <a href="https://twitter.com/pixels_online?ref_src=twsrc%5Etfw">@pixels_online</a> Kind Energy Party!
We are grateful to the community for the support and to Pixels for the opportunity to do this Event that represented a Milestone in KIND&#39;s History.
Thank you very much to the architect of the event <a href="https://twitter.com/KyleBlohm?ref_src=twsrc%5Etfw">@KyleBlohm</a>,&hellip; <a href="https://t.co/1NsrcaBeVL">https://t.co/1NsrcaBeVL</a> <a href="https://t.co/ib9Bat3jOl">pic.twitter.com/ib9Bat3jOl</a>
&mdash; KIND (@Kind_HQ) <a href="https://twitter.com/Kind_HQ/status/1781480503121444880?ref_src=twsrc%5Etfw">April 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Gaming

$PIXEL

Kind Hosts Massive 126K-Attendee Web3 Online Party In Pixels

The National Highway Traffic Safety Administration (NHTSA) has initiated a new investigation into Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&#8217;s handling of a December recall that affected 2 million vehicles that are equipped <a href="https://www.benzinga.com/topic/tesla-autopilot">with the Autopilot software.</a>
The recall involves all Tesla models, including Model Y, X, S, 3, and Cybertruck, and was intended to enact additional safeguards on the Autopilot system following a <a href="https://www.benzinga.com/government/23/12/36255070/teslas-autopilot-recall-what-went-wrong-with-the-self-driving-dream">series of concerning crashes. </a>
Yet with the NHTSA receiving reports of 20 crashes involving the vehicles post-update, the effectiveness of these measures is now under review, Reuters reported Friday. 
The new investigation adds to the regulatory scrutiny of Autopilot at a time when CEO Elon Musk is pushing for full self- driving, as Tesla is offering a month of free trials and plans to unveil <a href="https://www.benzinga.com/news/24/04/38396288/teslas-robotaxi-to-be-called-cybercab-elon-musk-says-self-driving-fleet-will-be-like-combination-of">its Robotaxi on Aug. 8.</a>
<h4 class="wp-block-heading">Regulatory Focus On Autopilot&#8217;s Safety Record</h4>
The latest NHTSA report highlights that despite the recall, new incidents involving Autopilot have surfaced, including several crashes. 
The regulator&#8217;s Office of Defects Investigation has noted these occurrences and has performed preliminary tests on vehicles that received the updated software.
The ongoing safety evaluation highlights a significant disconnect between user expectations of Autopilot's capabilities and its actual functionality, according to the regulatory agency. This &#8220;critical safety gap&#8221; has reportedly led to misuse by drivers, resulting in avoidable accidents. 
The agency criticized Tesla for using the term &#8220;Autopilot,&#8221; suggesting it &#8220;may lead drivers to believe that the automation has greater capabilities than it does and invite drivers to overly trust the automation.&#8221;
NHTSA&#8217;s findings suggest the updated Autopilot software still allows users to revert to previous settings, potentially undermining safety enhancements. Tesla did not respond to a request for comment from Reuters, the news agency reported. 
In its report, the NHTSA said Tesla&#8217;s approach to Autopilot functionality is markedly different from other auto manufacturers. 
<h4 class="wp-block-heading">Concerns Over Data Gaps, Crash Reporting</h4>
NHTSA has also raised concerns regarding the completeness of Tesla&#8217;s crash data reporting. 
The agency pointed out that Tesla's data collection primarily captures incidents where airbags are deployed, representing a fraction of all Autopilot-related crashes. 
This creates a substantial gap in understanding the full extent of issues associated with Autopilot use, the agency said. 
<h4 class="wp-block-heading">Calls For Stricter Regulation</h4>
This renewed probe by NHTSA is part of a series of investigations by various government agencies into Tesla&#8217;s Autopilot. 
The Justice Department and the Securities and Exchange Commission are also examining claims that Tesla may have misled consumers and investors about the capabilities of Autopilot, potentially overstating its effectiveness.
Market Reactions
Tesla shares dropped by 1.7% on Friday, yet they have climbed more than 13.7% over the week, representing the strongest weekly gain for the stock in almost a year.
Read now: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/04/38467013/tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-wh">Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What&#8217;s Driving Markets Friday?</a>
Photo courtesy of Tesla.

Equities

Large Cap

Tech

TSLA

Auto Watchdog Intensifies Probe Into Tesla's Autopilot Recall As Safety Concerns Mount

James M. Fejes Jr., owner of Flying High Investments LLC, faces the loss of his pilot license after <a href="https://www.benzinga.com/topic/cannabis-legalization">transporting cannabis within Alaska</a>. 
The Federal Aviation Administration (FAA) revoked his certificate despite Fejes&#8217;s argument that since cannabis is legal in Alaska, its transportation should be legal as well.
The trouble began when the FAA discovered that Fejes was using his private plane for cannabis distribution following a report from the state&#8217;s Alcohol and Marijuana Control Office. 
For starters, Fejes allegedly violated tracking requirements. While cultivation facilities must adhere to strict protocols, known as seed-to-sale tracking, Fejes misrepresented his transport methods, triggering the investigation.
Alaska, which has a land area of&nbsp;570,865.8 square miles&nbsp;and a water area of 94,722.2 square miles, is the largest US state by area. Small planes are essential for transporting supplies, food and people to hard-to-reach places across Alaska.
<h2 class="wp-block-heading">Pilot&#8217;s Appeal Falls On Deaf Ears</h2>
Fejes appealed to multiple bodies, including an administrative law judge and the National Transportation Safety Board, but was unsuccessful. His final appeal to the 9th Circuit challenged the FAA&#8217;s jurisdiction, arguing the transportation occurred solely within the state of Alaska. However, the court disagreed, asserting that Congress&#8217;s authority over interstate commerce extends to airspace regulation.
Fejes also claimed that because Alaska hadn't convicted him of any wrongdoing, the FAA had no right to revoke his license based on punishable actions. The 9th Circuit rejected Fejes&#8217;s arguments of misinterpreted law and overstepped authority and upheld the FAA&#8217;s decision.
The three-judge panel found that the Alaska law legalizing marijuana distribution did not override federal law that criminalizes the action.
"Although many states have legalized recreational marijuana, it continues to be a controlled substance federally," wrote Judge Ryan D. Nelson, one of the judges on the 9th Circuit, <a href="https://www.adn.com/alaska-news/crime-courts/2024/04/25/pilot-cant-fly-marijuana-to-retail-stores-in-alaska-even-if-sales-are-legal-federal-judges-rule/">reported</a> Anchorage Daily News.
<h2 class="wp-block-heading">It Could Be Worse</h2>
Even though the U.S. Department of Justice has directed prosecutors to exercise discretion in pursuing certain marijuana crimes in states where pot is legal, the opinion that "does not alter marijuana's status — it remains illegal under federal law."
The court opinion also ruled that even if Fejes' plane was only used within the state, it is considered an interstate form of transportation.
"Even if an airplane, like a car, is mainly used for intrastate activities, its operations could substantially impact interstate commerce," the panel found.
The FAA&#8217;s actions indicate a strict stance against such offenses, suggesting possible legal consequences for Fejes beyond having his license revoked. As a federal crime, distributing marijuana via aircraft, whether Fejes meant to break the law or not, could carry a sentence of at least one year.
Photo courtesy of Fly Around Alaska Flight School
Now Read: <a href="https://www.benzinga.com/short-sellers/24/04/38468155/trumps-stock-loss-means-millions-for-short-sellers-a-lot-of-his-businesses-go-belly-up-quickly">Trump&#8217;s Stock Loss Means Millions For Short Sellers &#8211; &#8216;A Lot Of His Businesses Go Belly Up, Quickly&#8217;</a>

Politics

Legal

Federal Court To Cannabis Pilot: No More Transporting Weed Around Alaska, FAA Revokes License Though Pot Is Legal There

<h1 class="wp-block-heading">Top Stories for April 26, 2024:</h1>
<ol>
<li>Anglo American (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTC">AAUKF</a>) rejected the <a href="https://www.benzinga.com/news/large-cap/24/04/38459129/anglo-american-rejects-bhps-highly-unattractive-bid-sets-proposal-deadline-for-may-22">$39-billion all-share takeover</a> bid from BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), calling it &#8220;highly unattractive&#8221; and undervalued.&nbsp;</li>
</ol>
The offer included conditions like demerging Anglo American's stakes in Amplats and Kumba Iron Ore and Anglo&#8217;s board cited the bid as opportunistic, dilutive to shareholder value and risky.
Despite BHP claiming a 31% premium, Anglo emphasized the proposal underestimated the value of its significant copper holdings.
See Also: <a href="https://www.benzinga.com/m-a/24/04/38469869/elliott-managements-1b-anglo-american-stake-ups-ante-as-mining-megamerger-collapses">Elliott Management&#8217;s $1B Anglo American Stake Ups Ante As Mining Megamerger Collapses</a>
<ol start="2">
<li>Gatos Silver Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) updated on its exploration at the Los Gatos district in Mexico, highlighting new mineral intercepts at the Cerro Los Gatos mine and appointing Chad Yuhasz as vice president. </li>
</ol>
CEO Dale Andres noted these findings will enhance the next resource estimate due in the third quarter of 2024.&nbsp;
Key intercepts included significant silver, zinc, lead, gold and copper grades.&nbsp;
The company is also preparing for expanded drilling in the second quarter of 2024 and has made progress in Greenfields exploration, with initial results showing potential deeper mineralization.
Also Read:<a href="https://www.benzinga.com/topic/mining"> </a><a href="https://www.benzinga.com/news/24/04/38435800/standard-lithium-activates-cutting-edge-plant-paves-way-for-cleaner-mining">Standard Lithium Activates Cutting-Edge Plant, Paves Way For Cleaner Mining</a>
<ol start="3">
<li>IperionX ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) successfully installed its commercial-scale HAMR titanium furnace at its new Titanium Manufacturing Campus in Virginia.&nbsp;</li>
</ol>
The furnace offers advantages like lower temperatures, higher efficiencies, shorter cycles and better product quality.&nbsp;
With the campus construction on schedule, the furnace commissioning is set for the second quarter of 2024, and production of titanium powder will start by mid-2024.&nbsp;
IperionX aims to develop a U.S. titanium supply chain using scrap and locally sourced minerals to produce high-performance titanium products more efficiently and with reduced environmental impact.
<ol start="4">
<li>Hycroft Mining Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYMC#NASDAQ">HYMC</a>) will be added to the Solactive Global Silver Miners Total Returns Index starting May 1, 2024.&nbsp;</li>
</ol>
Companies eligible for the Silver Index must have significant operations in silver mining, with substantial current or anticipated future revenues from silver mining or closely related activities.
This inclusion recognizes Hycroft&#8217;s significant operations in silver mining and its recent high-grade silver discovery at Hycroft Mine, providing its investors with greater liquidity and trading flexibility.
Now Read:<a href="https://www.benzinga.com/"> </a><a href="https://www.benzinga.com/news/24/04/38434933/nigeria-cracks-down-on-dormant-mining-titles-to-stop-license-racketeering">Nigeria Cracks Down On Dormant Mining Titles To Stop &#8216;License Racketeering&#8217;</a>
Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> to get connected with the Benzinga community! 
Photo: Shutterstock

Commodities

Global

AAUKF

GATO

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

Anglo American Rejects BHP Offer; Gatos Silver's Mineral Findings; IperionX Installs New Furnace And More: Friday's Top Mining Stories

Paul Rosenberg has been managing rapper Eminem for 27 years. Speaking at the <a href="http://benzinga.com/nfldraft/">Benzinga Sports Business Titans event</a>, Rosenberg shared how he initially met Eminem and the hurdles they overcame together on their path to success.
What Happened: Today, <a href="http://benzinga.com/topic/eminem">Eminem is one of the most successful</a> musicians on the planet. Without key individuals like Rosenberg and Dr. Dre, Eminem may have never succeeded in music.
In a story of perseverance, Rosenberg recalled his first interactions with the musician.
After a semi successful rap career, which included a deal with a local Detroit record label, Rosenberg was ready to go to law school at the age of 22 to become a music lawyer.
"I didn't want to be just a regular lawyer," Rosenberg told the live audience at Benzinga's Detroit headquarters at the Sports Business Titans event.
Rosenberg listened to rap music since he was 11 years old, which blossomed into rapping and later his music law aspirations.
While he was still connected to the local music scene, Rosenberg told musicians that he was going to be a music lawyer and could represent them in the future.
Local retail clothing store The Hip Hop Shop hosted open mics and rap battles that Rosenberg attended.
Detroit rapper Proof, who Rosenberg was going to represent as a lawyer, hosted battles and encouraged the future manager to stick around after battles and hear someone he thought was good and happened to be "a white boy."
Rosenberg said he remembers the "audition" like it was yesterday, with Eminem wearing an all-white tracksuit, appearing kinda scrubby looking and kinda pudgy.
"I thought he was really good."
Although, Rosenberg said it wasn't the best thing he had ever seen. Eminem's future manager later bought a $6 cassette from him a month or two later and said it was really good music, well-constructed, but wasn't there in terms of songs and deliveries.
"I'm interested, but I'm not like this is it."
Rosenberg received a call later on from a DJ at The Hip Hop Shop saying that he needed to hear Eminem's new music. That music was the bare bones of what would become "The Slim Shady LP."
"Then I was convinced."
Related Link: <a href="https://www.benzinga.com/general/gaming/23/11/35922646/eminem-joins-fortnites-big-bang-event-exclusive-slim-shady-skins-and-a-virtual-concert">Eminem Joins Fortnite&#8217;s Big Bang Event: Exclusive Slim Shady Skins, And A Virtual Concert?</a>
Lesson In Perseverance: Rosenberg himself being convinced in Eminem's music wasn't enough to turn the rapper into a success.
Rosenberg said his job was to find Eminem a record deal, but it didn't happen overnight.
"It wasn't a straight path, though. Nobody wanted to sign him," Rosenberg said.
Rosenberg said the landscape for hip hop was very different back then and being a white rapper was not seen as a favorable thing.
"I didn't give up."
Rosenberg said it just took the right someone hearing Eminem and helping him succeed.
"The someone was Dr. Dre."
Dr. Dre heard Eminem freestyle on the radio and also listened to a cassette later and knew it was the same talented musician he heard on the radio, which led to an eventual record deal with Aftermath Entertainment and Interscope Records.
"You shouldn't take no for an answer," Rosenberg said of his perseverance to get Eminem a deal.
Rosenberg said you hear this all the time, but it's so true.
Another important lesson shared with the live Benzinga audience was the 25+ year working relationship between Eminem and Rosenberg.
"I was very lucky that he's a loyal guy. Loyalty's very important."
Rosenberg added that loyalty is less and less valued by people today.
Rosenberg and Eminem were in Detroit for the 2024 NFL Draft, which included a food truck for the Mom's Spaghetti restaurant, which is based on a lyric in the rapper's song "Lose Yourself." The food truck also has official NFL licensed merchandise for sale during the draft in Detroit.
Eminem was one of the featured guests on stage during the 2024 NFL Draft alongside NFL Commissioner Roger Goodell.
"We know the commissioner now," Rosenberg said. "I call him Rog."
Rosenberg received the "Detroit Inspiration Award" from Benzinga during the Benzinga Sports Business Titans event.
Read Next: <a href="https://www.benzinga.com/general/entertainment/23/08/34080360/vivek-ramaswamys-shady-use-of-eminems-rap-draws-rebuke-from-marshall-mathers-himself">Vivek Ramaswamy&#8217;s &#8216;Shady&#8217; Use Of Eminem&#8217;s Rap Draws Rebuke — From Marshall Mathers Himself</a>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Benzinga Sports Business Titans: Unparalleled Athlete Access &amp; Insights Into Success" width="500" height="281" src="https://www.youtube.com/embed/93htkUYdGNc?start=8962&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo by Dustin Blitchok.

Entertainment

EXCLUSIVE: Eminem's Manager Paul Rosenberg Shares His Story With Multiplatinum Rapper — 'Nobody Wanted To Sign Him, I Didn't Give Up'

Society Pass Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) ("SOPA" or the "Company"), Southeast Asia's (SEA) next generation, e-commerce ecosystem, today announced that the board approved a proposed 1-for-15 shares reverse split of its common stock (the "Reverse Split").&nbsp; &nbsp;
Beginning with the opening of trading on&nbsp;May 1, 2024, the Company's common stock will begin trading on a post-Reverse Split basis on the Nasdaq Capital Market under the same symbol "SOPA", but under a new CUSIP number of 83370P201. The objective of the Reverse Split is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market.
Upon the effectiveness of the Reverse Split, every fifteen issued and outstanding shares of common stock with a par value of&nbsp;US$0.0001&nbsp;each will automatically be consolidated into one issued and outstanding common stock with a par value of&nbsp;US$0.0001&nbsp;each. No fractional shares will be issued as a result of the Reverse Split. Instead, any fractional shares that would have resulted from the Reverse Split will be rounded up to the next whole number. The Reverse Split affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares. The Reverse Split will also reduce the number of authorized shares by the same ratio as the Reverse Split. The Reverse Split was approved by the Company's board of directors. The Company has filed a certificate of change with the Secretary of State of Nevada.

Stock Split

SOPA

Society Pass Incorporated Announces 1-For-15 Reverse Stock Split, Will Begin At The Opening Of Trading On May 1, 2024

WIIM

AMC Entertainment shares are trading higher following a strong preliminary Q1 forecast.

Earnings

IONM

Assure Holdings Says Unaudited Financial Statements For Quarterly Periods Ended March 31 2023, June 30 2023 & Sept 30 2023 Should Not Be Relied Upon; Error Does Not Change Cash Position Of Co At End Of Non-Reliance Periods

<a href="https://news.bloomberglaw.com/daily-labor-report/lgbtq-health-care-bias-protections-gets-hhs-greenlight">https://news.bloomberglaw.com/daily-labor-report/lgbtq-health-care-bias-protections-gets-hhs-greenlight</a>
<ul>
<li>Health programs can't discriminate against LGBTQ patients</li>
<li>Rule follows US Supreme Court decision in Bostock</li>
</ul>
The Biden administration is bolstering civil rights protections for transgender and other LGBTQ people in a federal rule that could quickly face legal challenges.
The final rule (RIN <a href="https://public-inspection.federalregister.gov/2024-08711.pdf">0945-AA17</a>), announced Friday by the Department of Health and Human Services, reverses a Trump-era regulation and restores gender identity and sexual orientation discrimination protections under Section 1557 of the Affordable Care Act.
Section 1557 prohibits discrimination on the basis of race, color, national origin, sex, age, or disability by entities that primarily provide health care and receive federal funding. It is enforced by the HHS Office for Civil Rights.
The new rule "means that Americans across the country now have a clear way to act on their rights against discrimination when they go to the doctor, talk with their health plan, or engage with health programs run by HHS," HHS Secretary Xavier Becerra said in a statement.
The new rule comes as over 20 states have limited or banned gender-affirming care for children, according to <a href="https://www.aamc.org/news/states-are-banning-gender-affirming-care-minors-what-does-mean-patients-and-providers">KFF</a>. KFF also noted that over a dozen states are facing lawsuits over their youth gender affirming care policies.
The rule also follows the US Supreme Court's 2020 decision in <a href="https://www.bloomberglaw.com/public/document/BostockvClaytonCounty140SCt34204LEd2d11912019CourtOpinion?doc_id=XD099DOG000N">Bostock v. Clayton County</a>, in which the justices ruled that LGBTQ people are protected from discrimination under Title VII of the Civil Rights Act of 1964.
In light of Bostock, the Biden administration in 2021 announced it would interpret the word "sex" in the ACA to include gender identity.
Under the rule, the HHS will enforce its provisions for health insurance plans that do business through Medicare, Medicaid, or the Obamacare exchanges, including care provided under Medicare Part B, like that in a doctor's office.

Biotech

"LGBTQ Health Care Bias Protections Gets HHS Green Light; Health Programs Can't Discriminate Against LGBTQ Patients" - Bloomberg Law

First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.88 per share. This is a 22.81 percent decrease over earnings of $1.14 per share from the same period last year.

FCAP

First Cap Q1 EPS $0.88 Down From $1.14 YoY

FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!



Moving stocks this morning are strong early morning trading, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>HWH International (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwh-stock-quote/">HWH</a>) stock is rocketing more than 85% with strong early morning trading.</li>



<li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) shares are soaring over 50% with heavy pre-market trading.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is surging more than 30% with increasing trading activity on Thursday morning.</li>



<li>Brooge Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/brog-stock-quote/">BROG</a>) shares are rising over 21% as it also experiences strong trading today.</li>



<li>A.k.a. Brands (NYSE:<a href="https://investorplace.com/stock-quotes/aka-stock-quote/">AKA</a>) stock is increasing 17% without any clear news this morning.</li>



<li>Orgenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/orgs-stock-quote/">ORGS</a>) shares are gaining more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318209149&amp;type=PDF&amp;symbol=ORGS&amp;cdn=778bdb482c018a07a4dec09546e61eb2&amp;companyName=Orgenesis+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-04-02">following recent insider buying</a>.</li>



<li>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) stock is climbing over 15% despite a lack of news on Thursday.</li>



<li>AngioDynamics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ango-stock-quote/">ANGO</a>) shares are jumping more than 15% after releasing its <a href="https://www.nasdaq.com/press-release/angiodynamics-reports-fiscal-year-2024-third-quarter-financial-results-updates-fiscal">fiscal Q3 2024 earnings report</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is getting an over 14% boost as it continues to rally on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318212492&amp;type=PDF&amp;symbol=ADXN&amp;cdn=b99f04f9c986cd5ad74a2038763835fe&amp;companyName=Addex+Therapeutics+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-03">neurological company launch</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are up more than 13% without any clear news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Casa Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/casa-stock-quote/">CASA</a>) stock is plummeting over 31% after <a href="https://www.nasdaq.com/press-release/casa-systems-initiates-court-supervised-chapter-11-sale-process-for-businesses-2024">filing for bankruptcy</a>.</li>



<li>View (NASDAQ:<a href="https://investorplace.com/stock-quotes/view-stock-quote/">VIEW</a>) stock is diving more than 29% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318216587&amp;type=PDF&amp;symbol=VIEW&amp;cdn=229f694a9f04258b182e980a2525d125&amp;companyName=View+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-04">alongside a delisting notice</a>.</li>



<li>Globavend (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvh-stock-quote/">GVH</a>) shares are tumbling over 27% on Thursday morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is taking a more than 20% beating after <a href="https://finance.yahoo.com/news/flora-growth-corp-announces-launch-003700210.html">launching a share offering</a>.</li>



<li>Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) shares are sliding over 19% alongside its <a href="https://www.nasdaq.com/press-release/achilles-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and">Q4 2023 earnings report</a>.</li>



<li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/04/why-is-xti-aerospace-xtia-stock-up-89-today/">after rallying yesterday</a>.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are declining over 13% ahead of its <a href="https://www.nasdaq.com/press-release/reliance-global-group-schedules-fourth-quarter-2023-financial-results-and-business">Q4 conference call</a>.</li>



<li>Jiuzi (NASDAQ:<a href="https://investorplace.com/stock-quotes/jzxn-stock-quote/">JZXN</a>) stock is slipping more than 13% as it continues to fall <a href="https://www.nasdaq.com/press-release/jiuzi-holdings-enters-into-a-non-binding-loi-for-the-acquisition-of-shenzhen">on acquisition plans</a>.</li>



<li>Digital Health Acqsuitiion (NASDAQ:<a href="https://investorplace.com/stock-quotes/dhac-stock-quote/">DHAC</a>) shares are dipping over 13% without any apparent news.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock closes out our pre-market stock movers down more than 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-april-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

EIGR, ADXN and BROG are among premarket gainers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we get into all of the hottest news happening on Tuesday morning!



Moving stocks this morning are earnings reports, clinical trial data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) stock is rocketing close to 50% after <a href="https://www.nasdaq.com/press-release/biophytis-announces-its-2023-financial-results-and-provides-an-update-on-its-business">announcing its 2023 results</a>.</li>



<li>MyMD Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mymd-stock-quote/">MYMD</a>) shares are rising over 26% after revealing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224188&amp;type=PDF&amp;symbol=MYMD&amp;cdn=8720a94b32a7a67a8aeafa7ccea08ffe&amp;companyName=MyMD+Pharmaceuticals+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-08">securities purchase agreement</a>.</li>



<li>Acorda Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/acor-stock-quote/">ACOR</a>) stock is soaring more than 26% <a href="https://www.nasdaq.com/press-release/acorda-therapeutics-announces-nasdaq-delisting-notification-2024-04-03">ahead of its delisting</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) shares are surging over 26% without any clear news this morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is gaining nearly 17% despite a lack of news today.</li>



<li>Anghami (NASDAQ:<a href="https://investorplace.com/stock-quotes/angh-stock-quote/">ANGH</a>) shares are increasing more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224555&amp;type=PDF&amp;symbol=ANGH&amp;cdn=55a7014ffb2fa2fae4e6fc7d8965ee6d&amp;companyName=Anghami+Inc.&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-08">following an investor update</a>.</li>



<li>MediaCo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdia-stock-quote/">MDIA</a>) stock is climbing over 14% on Tuesday morning.</li>



<li>Brainstorm Cell (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcli-stock-quote/">BCLI</a>) shares are getting a more than 13% boost with an update on its <a href="https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-agreement-with-fda-on-a-special-protocol">Phase 3 clinical trial</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) stock is jumping over 13% as it <a href="https://seekingalpha.com/article/4682523-destiny-tech100-inc-dxyz-rose-800-percent-in-just-days-a-closer-look">continues a recent rally</a>.</li>



<li>RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) shares are up more than 12% on <a href="https://www.nasdaq.com/press-release/renovorx-announces-%2411.1-million-at-market-private-placement-2024-04-08">an offer to take it private</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vincerx Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/vinc-stock-quote/">VINC</a>) stock is crashing over 53% on <a href="https://www.nasdaq.com/press-release/vincerx-pharma-presents-positive-preliminary-phase-1-data-for-vip236-and-updates-on">preliminary Phase 1 clinical trial data</a>.</li>



<li>Focus Universal (NASDAQ:<a href="https://investorplace.com/stock-quotes/fcuv-stock-quote/">FCUV</a>) shares are plummeting more than 30% on Tuesday morning.</li>



<li>UTime (NASDAQ:<a href="https://investorplace.com/stock-quotes/wto-stock-quote/">WTO</a>) stock is diving over 23% after a major rally yesterday.</li>



<li>Vivos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvos-stock-quote/">VVOS</a>) shares are tumbling more than 22% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224743&amp;type=PDF&amp;symbol=VVOS&amp;cdn=01c96e38759646a4b342ce7c55cb1bd1&amp;companyName=Vivos+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-04-09">proposed public offering</a>.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) stock is taking an over 21% beating on Tuesday.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are decreasing more than 15% on <a href="https://seekingalpha.com/article/4682824-maxeon-solar-technologies-preliminary-q4-earnings-dont-buy-this-dip?source=content_type%3Areact%7Csection_asset%3Arelated-analysis%7Csection%3Aright_rail%7Cfirst_level_url%3Aarticle%7Cline%3A1%7Cpos%3Aundefined">preliminary earnings results</a>.</li>



<li>Eco Wave Power Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) stock is dropping over 14% after a <a href="https://investorplace.com/2024/04/why-is-eco-wave-power-wave-stock-up-115-today/">massive rally yesterday</a>.</li>



<li>Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) shares are sliding more than 12% on plans for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318223987&amp;type=PDF&amp;symbol=GHSI&amp;cdn=81af5524a2ccf8e9d81bd1343671bec4&amp;companyName=Guardion+Health+Sciences+Inc.&amp;formType=DEFM14A&amp;formDescription=Definitive+proxy+statement+relating+to+merger+or+acquisition&amp;dateFiled=2024-04-08">special shareholder meeting</a>.</li>



<li>DigiAsia (NASDAQ:<a href="https://investorplace.com/stock-quotes/faas-stock-quote/">FAAS</a>) stock is declining almost 12% after a rally yesterday.</li>



<li>Erayak Power Solution (NASDAQ:<a href="https://investorplace.com/stock-quotes/raya-stock-quote/">RAYA</a>) shares close out our pre-market stock movers down over 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

MYMD, MDIA and LIFW are among premarket gainers

Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!



Moving stocks this morning are earnings reports, an acquisition agreement, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is rocketing more than 97% alongside heavy pre-market trading.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are soaring close to 55% after releasing its <a href="https://www.nasdaq.com/press-release/dragonfly-energy-reports-fourth-quarter-2023-and-full-year-financial-results-2024-04">Q4 2023 earnings report</a>.</li>



<li>Macatawa Bank (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcbc-stock-quote/">MCBC</a>) stock is surging over 38% after <a href="https://www.globenewswire.com/news-release/2024/04/15/2863147/11955/en/Wintrust-Financial-Corporation-and-Macatawa-Bank-Corporation-Announce-Plans-to-Merge.html">signing an acquisition agreement</a>.</li>



<li>WiSA Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/wisa-stock-quote/">WISA</a>) shares are rising more than 26% <a href="https://www.nasdaq.com/press-release/wisa-technologies-announces-reverse-stock-split-2024-04-10">following a reverse stock split</a>.</li>



<li>Mobilicom (NASDAQ:<a href="https://investorplace.com/stock-quotes/mob-stock-quote/">MOB</a>) stock is gaining over 21% on plans to show off an <a href="https://www.nasdaq.com/press-release/mobilicom-to-unveil-unprecedented-comprehensive-solution-for-uncrewed-vehicle-systems">uncrewed vehicle system</a>.</li>



<li>HNR Acquisition (NYSEMKT:<a href="https://investorplace.com/stock-quotes/hnra-stock-quote/">HNRA</a>) shares are increasing more than 18% without any clear news this morning.</li>



<li>Shuttle Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/shph-stock-quote/">SHPH</a>) stock is climbing over 18% despite a lack of news.</li>



<li>Taoping (NASDAQ:<a href="https://investorplace.com/stock-quotes/taop-stock-quote/">TAOP</a>) shares are getting a more than 16% boost without any obvious news to report.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) stock is jumping over 16% on Tuesday morning.</li>



<li>Kaixin (NASDAQ:<a href="https://investorplace.com/stock-quotes/kxin-stock-quote/">KXIN</a>) shares are up more than 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) stock is diving over 29% on a <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-launch-of-proposed-underwritten-public-offering-2024-04-15">proposed public offering</a>.</li>



<li>Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) shares are tumbling more than 22% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318234211&amp;type=PDF&amp;symbol=CLDI&amp;cdn=ab45db11645ce0b64dd38dde47e4a59d&amp;companyName=Calidi+Biotherapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-04-15">proposed public offering</a>.</li>



<li>Inovio Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ino-stock-quote/">INO</a>) stock is taking an over 22% beating after <a href="https://finance.yahoo.com/news/inovio-announces-pricing-approximately-36-223900148.html">pricing an underwritten offering</a>.</li>



<li>MDJM (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdjh-stock-quote/">MDJH</a>) shares are sliding more than 15% on Tuesday morning.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is dropping over 12% this morning.</li>



<li>Qilian (NASDAQ:<a href="https://investorplace.com/stock-quotes/qli-stock-quote/">QLI</a>) shares are decreasing more than 10% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) stock is falling over 10% this morning.</li>



<li>US Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/useg-stock-quote/">USEG</a>) shares are slipping more than 10% on Tuesday.</li>



<li>Poseida Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pstx-stock-quote/">PSTX</a>) stock is dipping over 9% today.</li>



<li>OMNIQ (NASDAQ:<a href="https://investorplace.com/stock-quotes/omqs-stock-quote/">OMQS</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Addex Therapeutics GAAP EPS of -CHF 0.14, revenue of CHF 1.65M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) just reported results for the fourth quarter of 2023.<ul><li>Addex Therapeutics reported earnings per share of -$4.06.</li><li>The company reported revenue of $173,059.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/adxn-stock-earnings-addex-therapeutics-for-q4-of-2023/">ADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.